The interaction between human endothelial cells and leukocytes during immunologic and
inflammatory responses is in part mediated through the release of soluble mediators. We …

Alterations in the cellular redox potential by homocysteine promote endothelial cell (EC)
dysfunction, an early event in the progression of atherothrombotic disease. In this study, we …

The mechanism by which homocysteine causes endothelial cell (EC) injury and/or
dysfunction is not fully understood. To examine the stress-inducing effects of homocysteine …

Cultured bovine aortic endothelial cells (BAEs) synthesize and secrete type 1 plasminogen
activator inhibitor (PAI-1), an M, 50,000 glycoprotein which inhibits both urokinase and …

Objective—T cell-induced cytotoxicity, of which granzyme B is a key mediator, is believed to
contribute to the pathogenesis of inflammatory vascular diseases. In this report, we …

Type 1 plasminogen activator inhibitor (PAI-1), the primary inhibitor of tissue-type
plasminogen activator (t-PA), is found in plasma and platelets. PAI-1 circulates in complex …

We have previously demonstrated that the nonspecific binding of unfractionated heparin
(UFH) to plasma proteins has a marked modulating effect on its anticoagulant activity. Since …

The Quebec platelet disorder (QPD) is an autosomal dominant platelet disorder associated
with delayed bleeding and α-granule protein degradation. The degradation of α-granule, but …

The interaction between human endothelial cells and leukocytes during immunological and
inflammatory responses is in part mediated through the release of soluble mediators. We …

Type 1 plasminogen activator inhibitor (PAI-1), the primary inhibitor of tissue-type
plasminogen activator (t-PA), circulates as a complex with the abundant plasma …